肾性贫血是慢性肾脏病(chronic kidney disease,CKD)常见的并发症。CKD患者一方面常合并铁缺乏，另一方面又由于长期补铁存在铁过载风险。临床上常用的评估铁代谢的指标是铁蛋白和转铁蛋白饱和度，CKD患者由于慢性炎症状态，上述指标无法准确反映铁状态。静脉补铁和口服补铁各有优劣，多种新型铁剂的出现为未来肾性贫血铁剂治疗带来了新的选择，但其疗效仍需进一步临床验证。
Renal anemia is a common complication of chronic kidney disease (CKD). Iron deficiency is highly prevalent in patients with CKD. On the other hand, CKD patients are vulnerable to iron overload due to long-term iron supplement. Serum transferrin and transferrin saturation are traditionally used in the evaluation of iron status. However, due to the chronic inflammation in CKD patients, these biomarkers can not reflect iron status accurately. Oral and intravenous iron therapy both show advantages and disadvantages in anemia treatment. New iron agents bring new choices for iron therapy in renal anemia, while their efficacy needs further studies.
[1]Wish JB, et al.Iron Deficiency in CKD Without Concomitant Anemia[J].Kidney International Reports, 2021, 6(11):2752-2762
[2]Lee K-H, Y Ho, and D-C Tarng.Iron Therapy in Chronic Kidney Disease: Days of Future Past[J].International Journal of Molecular Sciences, 2021, 22(3):1008-1008
[3]Malyszko J, JS Malyszko, and J Matuszkiewicz-Rowinska.Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease[J].Expert Opinion On Therapeutic Targets, 2019, 23(5):407-421
[4]Besarab A and TB Drueke.The problem with transferrin saturation as an indicator of iron 'sufficiency' in chronic kidney disease[J].Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 2021, 36(8):1377-1383
[5]Bazeley JW and JB Wish.Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review[J].American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, 2022, 79(6):868-876
[6]Stancu S, et al.Bone marrow iron,iron indices,and the response to intravenous iron in patients with non-dialysis-dependent CKD[J].Am J Kidney Dis, 2010, 55(4):639-647
[7]Tomasz G, W Ewa, and M Jolanta.Biomarkers of iron metabolism in chronic kidney disease[J].International Urology and Nephrology, 2021, 53(5):935-944
[8]Ratcliffe LE, et al.Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale[J].Am J Kidney Dis, 2016, 67(4):548-558
[9]Yamamoto H, et al.Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease[J].Renal Replacement Therapy, 2017, 3(1):1-46
[10]Kshirsagar AV and X Li.Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients[J].Advances In Chronic Kidney Disease, 2019, 26(4):292-297
[11]Shepshelovich D, et al.Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis[J].Am J Kidney Dis, 2016, 68(5):677-690
[12]Kliger AS, et al.KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD[J].Am J Kidney Dis, 2013, 62(5):849-859
[13]Li L, et al.Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials[J].Renal Failure, 2022, 44(1):1112-1122
[14]Khoury A, KA Pagan, and MZ Farland.Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults[J].The Annals of Pharmacotherapy, 2021, 55(2):222-229
[15]Pergola PE and NP Kopyt.Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension[J].Am J Kidney Dis, 2021, 78(6):846-856
[16]Pisani A, et al.Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial[J].Nephrol Dial Transplant, 2015, 30(4):645-652
[17]Nagaraju SP, et al.Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial[J].BMC Nephrol, 2013, 14(-):64-64
[18]Nissenson AR, et al.Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients[J].Am J Kidney Dis, 2003, 42(2):325-330
[19]Barraclough KA, et al.A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial[J].Nephrol Dial Transplant, 2012, 27(11):4146-4153
[20]Onken JE, et al.Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial[J].Nephrol Dial Transplant, 2014, 29(4):833-842
[21]Auerbach M, et al.A prospective,multi-center,randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial[J].Am J Hematol, 2019, 94(9):1007-1014
[22]Bhandari S, et al.Safety and efficacy of iron isomaltoside 1000ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized,open-label,comparative trial[J].Nephrol Dial Transplant, 2021, 36(1):111-120
[23]Glaspy JA, et al.Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review[J].Ther Clin Risk Manag, 2020, 16(-):245-259
[24]Fishbane SN, et al.Ferric pyrophosphate citrate (Triferic) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients[J].Nephrol Dial Transplant, 2015, 30(12):2019-2026
[25]Shoji S, et al.Greater potency of darbepoetin-alpha than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients[J].Eur J Haematol, 2013, 90(3):237-244
[26]Fishbane S, et al.Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study[J].Journal of the American Society of Nephrology : JASN, 2022, 33(4):850-866
